Q&A with Terry Novak, Norwich Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Terry Novak, Norwich Pharmaceuticals
A Q&A with Terry Novak, president of Norwich Pharmaceuticals, on recent industry trends.

Pharmaceutical Technology
Volume 35, Issue 8, pp. 81

Q&A with
Terry Novak, president of Norwich Pharmaceuticals


Terry Novak
PharmTech:
What is the biggest industry challenge you're now facing?

Novak:
The contract manufacturing organization (CMO) industry faces a reputation issue. People think we're mediocre. There's still a stigma, a perception that Big Pharma can do drug manufacturing better than outsourcing providers. While that perception has slightly changed during the past five years, proving the case for CMO partnership remains our most time-intensive challenge. CMOs have to be as good as the customer's own manufacturing, which means delivering finished product on time, and right the first time. The greatest strength the CMO industry now has is its strong regulatory compliance. Where CMOs need to do a better job is on-time delivery. For specialty and small pharmaceutical companies, we are their internal supply, and we always have to remember that. I think a lot of CMOs have lost their customer focus due to the financial issues that have affected their businesses during the past few years.

PharmTech:
Do you see a new industry trend emerging?

Novak:
Drug delivery is still a hot topic. We see many companies trying to extend the patent life of an existing product before it loses exclusivity. Specifically, nanotechnology has been talked about forever, but no one has put it to commercial use yet.

Everyone is still talking about ePedigree. We were preparing for the California legislation about two years ago to force this issue into becoming a trend, and although it didn't happen, I believe it's inevitable. On the packaging end, this will be a big emerging area that we're going to have to address.

PharmTech:
What is the most common demand your clients are currently making of you?

Novak:
Lately it's been formulation development for products that are poorly soluble. They're difficult to manufacture, and outsourcing providers should be looking to solve that problem. It's an area that we've expanded into, whether it's highly potent compounds or complex controlled-release delivery. During the next few years, growth in the contract manufacturing business will be achieved by companies that can provide a quality solution to complex formulations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
10%
Regulatory compliance
33%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here